wrn helicase

Werner syndrome RecQ helicase-IN-1 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.

ML216 (CID-49852229) is a small molecule inhibitor of BLM helicase with an IC50 of 1.8 μM, demonstrating 28-fold selectivity against the related helicases RECQ1, RECQ5, and E. coli UvrD (IC50s > 50 μM).

GSK4418959 (IDE275) is an orally active, non-covalent, reversible, and selective WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used to study MSI-H related research.

NCGC00029283 is a potent inhibitor of Werner syndrome helicase-nuclease (WRN), displaying inhibitory activity against WRN helicase with an IC 50 value of 2.3 μM. Additionally, it exhibits inhibitory effects on Bloom syndrome protein helicase (BLM) and Fanconi anemia group J protein helicase (FANCJ) with IC 50 values of 12.5 μM and 3.4 μM, respectively.

GSK_WRN4 is a WRN helicase inhibitor with anticancer activity. It induces DNA double-strand breaks and inhibits MSI tumor cell growth, making it useful in cancer research.

WRN inhibitor 7 (Compound h6), a potent inhibitor of Werner syndrome helicase, demonstrates effective suppression of WRN's helicase and ATPase activities with IC50 values of 9.8 μM and 15.8 μM, respectively. This compound is utilized in the study of microsatellite instable (MSI) cancers [1].

WRN Inhibitor 4 (Example 107), a cyclic vinyl sulfone-based compound, serves as an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN). This inhibitor is applicable in cancer research [1].

Werner syndrome RecQ helicase-IN-4 is an effective inhibitor of Werner syndrome RecQ DNA helicase (WRN), exhibiting anticancer and antiproliferative activities, used for colorectal and gastric cancer research.

Werner syndrome RecQ helicase-IN-3, a potent and orally active inhibitor of Werner syndrome RecQ helicase (WRN), exhibits anticancer and antiproliferative activities with an IC50 value of 0.06 µM.

NCGC00063279 is a novel inhibitor of the werner syndrome helicase-nuclease (wrn) helicase

WRN inhibitor 13 is an inhibitor of the WRN helicase with a pIC50 value ranging from 6 to 7.

KWR095 is an orally active inhibitor of WRN, demonstrating an IC50 of 0.032 μM against WRN ATPase. It disrupts the double-stranded helicase activity of WRN and inhibits tumor cell proliferation, exhibiting antitumor properties.

Werner syndrome RecQ helicase-IN-2 is an effective inhibitor of Werner syndrome RecQ DNA helicase (WRN), used in studying colorectal and gastric cancer.

GSK_WRN2 is a potent, selective covalent inhibitor of the WRN helicase, which targets replication stress caused by the amplification of DNA (TA)n dinucleotide repeats. It can be utilized in research focusing on microsatellite instability (MSI) cancers.

WRN Inhibitor 2 (example 118), a potent inhibitor of the WRN (Werner Syndrome ATP-dependent helicase enzyme), exhibits a pIC50 value of 7.0 or greater [1].

WRN Inhibitor 3 (example 110), a cyclic vinyl sulfone-based compound, serves as an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN). It is utilized in cancer research [1].

WRN inhibitor 12 (compound 5) serves as an inhibitor for the WRN helicase.

WRN inhibitor 17 (Compound 250) is an orally active inhibitor of Werner syndrome ATP-dependent helicase (WRN), specifically targeting the helicase domain activity of WRN. It holds potential for use in cancer research.

H3B-968 is a potent inhibitor of Werner syndrome protein (WRN) with an IC50 of approximately 10 nM, targeting its helicase, ATPase, and exonuclease activities. While WRN is known for its synthetic lethal activity in cancer studies, H3B-968 specifically inhibits WRN's helicase function through competitive ATP antagonism [1].

WRN Inhibitor 5 (Example 157), a cyclic vinyl sulfone-based compound, serves as an inhibitor of Werner Syndrome ATP-dependent helicase enzyme (WRN). It is utilized in cancer research [1].

NSC 617145 (NSC617145) is an inhibitor of WRN helicase that inhibits the ATPase, but not exonuclease, activity of WRN helicase in a concentration-dependent manner.

WRN Inhibitor 1 (example 7) is an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN), selectively targeting its helicase domain. This compound is potentially useful for cancer research [1].

WRN inhibitor 11 (Example 17) is an orally effective inhibitor of WRN helicase, with an IC50 of 63 nM.

MIRA-1 (WRN Helicase Inhibitor) is a restorer of wild-type p53 conformation cellular function and selectively inhibits Werner syndrome WRN helicase activity with an IC50 of 20 µM.